Plain-English translation of NCT07072728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing NPX-5 (psilocybin) paired with professional therapy to help cancer patients who are experiencing significant emotional distress, anxiety, or difficulty adjusting to their diagnosis. Participants will receive one dose of the medication under medical supervision, combined with preparation sessions and therapy support. The study compares three different doses to see which works best and is safest.
Many cancer patients experience serious emotional and anxiety symptoms that don't always respond well to standard treatments alone. This trial is exploring whether this medication, when used alongside therapy in a controlled setting, might help reduce these emotional symptoms and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You will have screening visits to confirm you qualify, then three preparation sessions (some in person, some by phone or video) with a trained therapist to prepare you for the experience. On Day 14, you will come to the clinic and take a single dose of the medication under close medical supervision while a therapist is present to support you. After that, you'll have follow-up appointments and phone calls over about 10 weeks to check how you're doing. Some visits will be in person, and some can be done by phone or video for convenience.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Australia